Figure S5.
Wdfy4 is dispensable for in vitro cross-presentation of IC by macrophage/moDCs. (A) In vitro proliferation of OT-I cultured for 3 days with macrophage/moDCs or cDC2 from WT and Wdfy4−/− mice and the indicated dose of OVA-IC. (B) Frequency of OT-I proliferation from A. Data represent mean ± SEM of two independent experiments. Two-way ANOVA with Sidak’s multiple comparisons test. (C) Gating strategy (left) and the percentage in spleen (right) for cDC2a, cDC2b, and DC3s from spleen of WT or Δ1+2+3 mice. Pregated on live B220− CD11c+ MHC-II+ population. Data are represented as mean values ± SD combined from two independent experiments. Multiple t tests. ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001. (D) Graphical abstract. Refer to the image caption for details.

Wdfy4 is dispensable for in vitro cross-presentation of IC by macrophage/moDCs. (A) In vitro proliferation of OT-I cultured for 3 days with macrophage/moDCs or cDC2 from WT and Wdfy4−/− mice and the indicated dose of OVA-IC. (B) Frequency of OT-I proliferation from A. Data represent mean ± SEM of two independent experiments. Two-way ANOVA with Sidak’s multiple comparisons test. (C) Gating strategy (left) and the percentage in spleen (right) for cDC2a, cDC2b, and DC3s from spleen of WT or Δ1+2+3 mice. Pregated on live B220− CD11c+ MHC-II+ population. Data are represented as mean values ± SD combined from two independent experiments. Multiple t tests. ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001. (D) Graphical abstract.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal